After 89bio (ETNB) provided results from the Phase 2b ENLIVEN study of pegozafermin in F2/F3 non-alcoholic steatohepatitis, or NASH, Morgan Stanley analyst Michael Ulz noted that pegozafermin is a potential competitor to Akero Therapeutics’ (AKRO) efruxifermin, or EFX, which is expected to enter Phase 3 in 2023. Despite the challenges of cross trial comparison, the firm continues to believe EFX has "a competitive efficacy profile" and believes data for pegozafermin further validate FGF21 as a target for NASH that drives fibrosis improvement. In addition, another successful study in NASH supports a continued positive shift in sentiment, according to the firm, which reiterates an Overweight rating and $65 price target on Akero shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AKRO:
- 89bio NASH data show high statistical significance, says Cantor Fitzgerald
- Akero Therapeutics price target raised to $58 from $50 at Canaccord
- Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
- Akero Therapeutics reports Q4 EPS (49c), consensus (80c)
- Morgan Stanley upgrades Akero Therapeutics into ‘multiple key catalysts’